{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T17:29:59Z","timestamp":1773077399872,"version":"3.50.1"},"reference-count":16,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,5]]},"DOI":"10.1182\/blood.2019004371","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T02:16:17Z","timestamp":1591755377000},"page":"2237-2240","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation"],"prefix":"10.1182","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4994-7719","authenticated-orcid":false,"given":"Elisa","family":"Diral","sequence":"first","affiliation":[{"name":"Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy;"},{"name":"Division of Hematology, San Gerardo Hospital, Monza, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Antolini","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-6491","authenticated-orcid":false,"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[{"name":"San Eugenio Hospital, Rome, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Le Coutre","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Charit\u00e9 - Humboldt-Universit\u00e4t, Campus Virchow, Berlin, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Martino","sequence":"additional","affiliation":[{"name":"Hematology, Bianchi Melacrino Morelli Hospital, Reggio Calabria, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Pungolino","sequence":"additional","affiliation":[{"name":"Hematology, Niguarda Ca' Granda Hospital, Milan, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Elena","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy;"},{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micaela","family":"Bergamaschi","sequence":"additional","affiliation":[{"name":"Hematology Clinic, IRCSS AOU S. Martino-IST, University of Genoa, Genoa, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[{"name":"Division of Haematology, Jewish General Hospital, McGill University, Montreal, QC, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eros","family":"Di Bona","sequence":"additional","affiliation":[{"name":"Hematology, San Bortolo Hospital, Vicenza, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Gozzini","sequence":"additional","affiliation":[{"name":"Hematology, AOU Careggi, University of Firenze, Firenze, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-7112","authenticated-orcid":false,"given":"Marcio","family":"Andrade-Campos","sequence":"additional","affiliation":[{"name":"Haematology, Hospital Universitario Miguel Servet, Zaragoza, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[{"name":"Hematology, University of Catania, Catania, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-0812","authenticated-orcid":false,"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[{"name":"Oncohematology Division, IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation, University of Milan, Milan, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Pirola","sequence":"additional","affiliation":[{"name":"GalSeq s.r.l., Bresso, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1633-6310","authenticated-orcid":false,"given":"Diletta","family":"Fontana","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8640-2462","authenticated-orcid":false,"given":"Jessica","family":"Petiti","sequence":"additional","affiliation":[{"name":"University of Turin, Turin, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Luisa","family":"Bonanomi","sequence":"additional","affiliation":[{"name":"Clioss s.r.l., Nerviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Crivori","sequence":"additional","affiliation":[{"name":"Clioss s.r.l., Nerviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4198-9620","authenticated-orcid":false,"given":"Rocco","family":"Piazza","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy;"},{"name":"Division of Hematology, San Gerardo Hospital, Monza, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Fava","sequence":"additional","affiliation":[{"name":"University of Turin, Turin, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6058-515X","authenticated-orcid":false,"given":"Carlo","family":"Gambacorti-Passerini","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy;"},{"name":"Division of Hematology, San Gerardo Hospital, Monza, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"10","key":"2020110511275841600_B1","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study","volume":"90","author":"Mori","year":"2015","journal-title":"Am J Hematol"},{"issue":"12","key":"2020110511275841600_B2","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia","volume":"13","author":"van Dongen","year":"1999","journal-title":"Leukemia"},{"issue":"2","key":"2020110511275841600_B3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1078-0432.CCR-13-1988","article-title":"Deep molecular response in chronic myeloid leukemia: the new goal of therapy?","volume":"20","author":"Mahon","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2020110511275841600_B4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"2020110511275841600_B5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2020110511275841600_B6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"key":"2020110511275841600_B7","first-page":"1","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study","volume":"24","author":"Shah","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"2020110511275841600_B8","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/j.ejca.2013.06.018","article-title":"Imatinib discontinuation in chronic phase myeloid leukemia patients in sustained complete molecular response: a randomised trial the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)","volume":"49","author":"Thielen","year":"2013","journal-title":"Eur J Cancer"},{"issue":"12","key":"2020110511275841600_B9","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.3109\/10428194.2013.831092","article-title":"Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience","volume":"55","author":"Benjamini","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2020110511275841600_B10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-018-0125-0","article-title":"Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients","volume":"8","author":"Hern\u00e0ndez-Boluda","year":"2018","journal-title":"Blood Cancer J"},{"issue":"4","key":"2020110511275841600_B11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/bjh.15826","article-title":"Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study","volume":"185","author":"De Bruijn","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"2020110511275841600_B12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000499329","article-title":"Interruption or discontinuation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia: a retrospective cohort study (SPARKLE) in Belgium","volume":"142","author":"Devos","year":"2019","journal-title":"Acta Haematol"},{"issue":"8","key":"2020110511275841600_B13","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3324\/haematol.2018.205054","article-title":"Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice","volume":"104","author":"Fava","year":"2019","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2020110511275841600_B14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2019-131500","article-title":"Introducing a predictive score for successful treatment free remission in chronic myeloid leukemia (CML) [abstract]","volume":"134","author":"Claudiani","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2020110511275841600_B15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2019-124408","article-title":"Prognostication of molecular relapses after dasatinib or nilotinib discontinuation in chronic myeloid leukemia (CML): a FI-LMC STOP 2G-TKI study update","volume":"134","author":"Rea","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2020110511275841600_B16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2019-123719","article-title":"The TKI-free duration after a first discontinuation attempt that failed in CP CML patients is a predictive factor of TKI-free remission after a second attempt","volume":"134","author":"Legros","year":"2019","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/19\/2237\/1780366\/bloodbld2019004371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/19\/2237\/1780366\/bloodbld2019004371.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T16:29:02Z","timestamp":1604593742000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/136\/19\/2237\/460734\/Increased-tumor-burden-in-patients-with-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":16,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2020,11,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019004371","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]}}}